ImmunoBrain Announces Nature Medicine Publication and Late-Breaking AAIC 2026 Presentation for IBC-Ab002 in Early Alzheimer's Disease

- Phase 1b results offer early positive signal of checkpoint immunotherapy in a clinical setting for Alzheimer's NEW YORK, July 14, 2026 /PRNewswire/ -- ImmunoBrain, a clinical-stage biopharmaceutical company developing immunotherapies for neurodegenerative diseases, today announced the...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.